aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Enable Injections was founded with the core mission of revolutionizing patient care through innovative drug delivery systems. The company focuses on developing and manufacturing on-body delivery solutions designed to enhance the patient experience. Their flagship product, enFuse®, offers a wearable, user-friendly, and flexible drug delivery system that accommodates various viscosities, volumes, delivery times, and administration sites. Enable Injections primarily targets the healthcare market, aiming to provide patients and healthcare providers with more convenient and efficient treatment options.
Notable figures associated with Enable Injections include key investors from prominent venture capital firms specializing in healthcare innovations. The company has achieved significant milestones, including successful clinical trials and partnerships with major pharmaceutical companies. Enable Injections' impact is evident in its contribution to improving patient compliance and comfort, ultimately leading to better health outcomes and streamlined treatment processes.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Drug Delivery Systems
Technology
Medical Devices
Tags
Healthtech
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Enable Injections founded?
Enable Injections was founded in 2011.
Where is Enable Injections’s headquarters located?
Enable Injections’s headquarters is located in Cincinnati, OH, US.
When was Enable Injections’s last funding round?
Enable Injections’s most recent funding round was for $215M (USD) in January 2022.
How many employees does Enable Injections have?
Enable Injections has 181 employees as of Feb 5, 2024.
How much has Enable Injections raised to-date?
As of July 05, 2023, Enable Injections has raised a total of $347M (USD) since Jan 27, 2022.
Add Comparison
Total Raised to Date
$347M
USD
Last Update Jan 27, 2022
Last Deal Details
$215M
USD
Jan 27, 2022
Series C
Total Employees Over Time
181
As of Feb 2024
Enable Injections Address
2863 E. Sharon Road
Cincinnati,
Ohio
45241
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts